Vnitr Lek 2014, 60(9):787-790

Diabetes mellitus and pancreatic cancer - cause or result?

Pavel Škrha
II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Michal Anděl, CSc.

Pancreatic cancer is a malignancy with a poor prognosis. Its increased incidence was observed in diabetic patients in the past. However, there is no evidence, whether diabetes is a risk factor for neoplastic transformation, or if it arises secondarily as a result of the tumor. The key is an early detection of cancer to perform pancreatectomy - the only possible curative therapy yet. This requires early diagnostic markers.

Keywords: diabetes mellitus; pancreatectomy; pancreatic cancer

Received: May 25, 2014; Accepted: July 27, 2014; Published: September 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha P. Diabetes mellitus and pancreatic cancer - cause or result? Vnitr Lek. 2014;60(9):787-790.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928-1937. Go to original source... Go to PubMed...
    2. Li D, Tang H, Hassan MM et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22(2): 189-97. Go to original source... Go to PubMed...
    3. Ben Q, Cai Q, Li Z et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case-control study. Eur J Cancer 2011; 47(2): 248-254. Go to original source... Go to PubMed...
    4. Chari ST, Leibson CL, Rabe KG et al. Pancreatic Cancer-Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer. Gastroenterology 2008; 134(1): 95-101. Go to original source... Go to PubMed...
    5. Mizuno S, Nakai Y, Isayama H et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology 2013; 13(3): 285-289. Go to original source... Go to PubMed...
    6. Pannala R, Leirness JB, Bamlet WR et al. Prevalence and Clinical Profile of Pancreatic Cancer-Associated Diabetes Mellitus. Gastroenterology 2008; 134(4): 981-987. Go to original source... Go to PubMed...
    7. Permert J, Ihse I, Jorfeldt L et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159(2): 101-107. Go to PubMed...
    8. Jee SH, Ohrr H, Sull JW et al. Fasting serum glucose level and cancer risk in Korean men and women. Jama 2005; 293(2): 194-202. Go to original source... Go to PubMed...
    9. Gapstur SM, Gann PH, Lowe W et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283(19): 2552-2558. Go to original source... Go to PubMed...
    10. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 2006;7(2): 85-96. Go to original source... Go to PubMed...
    11. Asano T, Yao Y, Shin S et al. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 2005; 65(20): 9164-9168. Go to original source... Go to PubMed...
    12. Tanno S, Tanno S, Mitsuuchi Y et al. AKT Activation Up-Regulates Insulin-like Growth Factor I Receptor Expression and Promotes Invasiveness of Human Pancreatic Cancer Cells. Cancer Res 2001; 61(2): 589-593. Go to original source... Go to PubMed...
    13. Asano T, Yao Y, Zhu J et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23(53): 8571-8580. Go to original source... Go to PubMed...
    14. Pantalone D, Ragionieri I, Nesi G. Improved survival in small pancreatic cancer. Dig Surg 2001; 18(1): 41-46. Go to original source... Go to PubMed...
    15. Fisher WE, McCullough PJ, Ray MB et al. Diabetes enhances growth of pancreatic carcinoma cells. Surgery 1988; 104(2): 431-436. Go to PubMed...
    16. Butler AE, Galasso R, Matveyenko A et al. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010; 53(1): 21-26. Go to original source... Go to PubMed...
    17. Basso D et al. β-Cell function in pancreatic adenocarcinoma. Pancreas 1994; 9: 332-335. Go to original source... Go to PubMed...
    18. Agustsson T, D'souza MA, Nowak G et al. Mechanisms for skeletal muscle insulin resistance in patients with pancreatic ductal adenocarcinoma. Nutrition 2011; 27(7-8): 796-801. Go to original source... Go to PubMed...
    19. Permert J, Adrian TE, Jacobsson Pet al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? The Am J Surg.1993; 165(1): 61-67. Go to original source... Go to PubMed...
    20. Permert J, Ihse I, Jorfeldt L et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80(8): 1047-1050. Go to original source... Go to PubMed...
    21. Basso D, Greco E, Fogar P et al. Pancreatic cancer-associated diabetes mellitus: An open field for proteomic applications. Clin Chim Acta 2005; 357(2): 184-189. Go to original source... Go to PubMed...
    22. Fogar P, Basso D, Pasquali C et al. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin Chim Acta.1998; 277(2): 181-189. Go to original source... Go to PubMed...
    23. Pannala R, Basu A, Petersen GM et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. The Lancet Oncol 2009; 10(1): 88-95. Go to original source... Go to PubMed...
    24. Noy A, Bilezikian JP. Diabetes and pancreatic cancer: Clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab 1994; 79(5): 1223-1231. Go to original source...
    25. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 2010; 11(3): 203-212. Go to PubMed...
    26. Poruk KE, Gay DZ, Brown K et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013; 13(3): 340-351. Go to original source...
    27. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85(4): 350-355.
    28. Kosanam H, Prassas I, Chrystoja CC et al. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics 2013; 12(10): 2820-2832. Go to original source... Go to PubMed...
    29. Park HD, Kang ES, Kim JW et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics 2012; 12(23-24): 3590-3597. Go to original source... Go to PubMed...
    30. Zhang P, Zou M, Wen X et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int J Cancer 2014; 134(11): 2646-2655. Go to original source... Go to PubMed...
    31. Willumsen N, Bager CL, Leeming DJ et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 2013; 13:554. Dostupné z DOI: <http://doi:10.1186/1471-2407-13-554>. Go to original source... Go to PubMed...
    32. Fric P, Zavoral M. Early diagnosis of pancreatic adenocarcinoma: role of stroma, surface proteases, and glucose-homeostatic agents. Pancreas 2012; 41(5): 663-670. Go to original source... Go to PubMed...
    33. Bracci PM, Zhou M, Young S et al. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer 2012; 118(21): 5384-5394. Go to original source... Go to PubMed...
    34. Chung HW, Lim JB, Jang S et al. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 2012; 103(9): 1714-1721. Go to original source... Go to PubMed...
    35. Ikeda Y, Tanji E, Makino N et al. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res 2012; 10(2): 259-269. Go to original source... Go to PubMed...
    36. LaConti JJ, Shivapurkar N, Preet A et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011; 6(6): e20687. Go to original source... Go to PubMed...
    37. Morimura R, Komatsu S, Ichikawa D et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105(11): 1733-1740. Go to original source... Go to PubMed...
    38. Kawaguchi T, Komatsu S, Ichikawa D et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108(2): 361-369. Go to original source... Go to PubMed...
    39. Liu R, Chen X, Du Y et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58(3): 610-618. Go to original source... Go to PubMed...
    40. Zhu ZM, Xu YF, Su QJ et al. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma. Mol Cell Biochem 2014; 388(1-2): 39-49. Go to original source... Go to PubMed...
    41. Liu J et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012; 131(3): 683-691. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.